SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

28 Jul 2025 Evaluate
The sales is pegged at Rs. 9698.80 millions for the June 2025 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 10632.00 millions during the year-ago period.A good growth in profit of 32.68% reported to Rs. 1131.40  millions over Rs. 852.70 millions of corresponding previous quarter.Operating profit for the quarter ended June 2025 rose to 2252.50 millions as compared to 1883.90 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 9698.80 10632.00 -8.78 9698.80 10632.00 -8.78 52857.10 43901.10 20.40
Other Income 1809.20 367.60 392.17 1809.20 367.60 392.17 2073.50 2020.60 2.62
PBIDT 2252.50 1883.90 19.57 2252.50 1883.90 19.57 12477.90 8199.80 52.17
Interest 232.30 248.80 -6.63 232.30 248.80 -6.63 1145.60 1071.00 6.97
PBDT 2020.20 1635.10 23.55 2020.20 1635.10 23.55 11332.30 7128.80 58.97
Depreciation 594.40 518.50 14.64 594.40 518.50 14.64 2220.90 2052.60 8.20
PBT 1425.80 1116.60 27.69 1425.80 1116.60 27.69 9111.40 5076.20 79.49
TAX 294.40 263.90 11.56 294.40 263.90 11.56 2197.40 1164.00 88.78
Deferred Tax 98.10 -10.40 -1043.27 98.10 -10.40 -1043.27 203.00 39.20 417.86
PAT 1131.40 852.70 32.68 1131.40 852.70 32.68 6914.00 3912.20 76.73
Equity 13248.20 13229.50 0.14 13248.20 13229.50 0.14 13243.50 13229.50 0.11
PBIDTM(%) 23.22 17.72 31.07 23.22 17.72 31.07 23.61 18.68 26.39

Piramal Pharma Share Price

148.75 -0.15 (-0.10%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×